ซื้อ Lucius Nintedanib ออนไลน์
ซื้อ Lucius Nintedanib ออนไลน์

ซื้อ Lucius Nintedanib ออนไลน์

Price range: EUR 2,691.68 through EUR 3,800.00

3,000+ vendidos
Preco promocional

Farmacia fisica em Hong Kong, 100% de autenticidade garantida

Destaques do produto

PDGFR-α/β FGFR1-3 VEGFR1-3 CSF1R FLT-3 ， 2014 10 IPF ，

Garantias de servico

Envio direto internacionalFarmacia autorizadaRevisado por farmaceuticoGarantia de autenticidade

Especificacoes

Especificacao
100mg*60 150mg*60
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong
SKU: n.d. Categorias: , Etiqueta: Marca:

Informacoes do produto

Nome em ingles
Nintedanib
Nome generico
Nintedanib

Especificacoes

Especificacao
100mg*60 150mg*60
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

Detalhes completos

Indicacoes

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Mecanismo de acao

， RTK nRTK RTK PDGFR α β FGFR 1 3 VEGFR 1 3 1 CSF1R Fms -3 FLT-3 FLT-3 ， ILD ATP ， ， ILD

Farmacologia

12.1 Como funciona ， (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1 3 (VEGFR) 1 3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 ， (ILD) (ATP) ，

Precaucoes

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Dosagem (2.3)] 5.2 DILI ， DILI

Interacoes medicamentosas

7.1 P- (P-gp) CYP3A4 P-gp ， CYP3A4 [ (12.3)] P-gp CYP3A4 ， 60% P-gp CYP3A4 [ (12.3)] ，

Reacoes adversas

[ Precaucoes(5.2)] [ Precaucoes(5.3)] - [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1 ，

Package Insert

Ingredients

11 ， [ Como funciona(12.1)] ， 1H- -6- ，2,3- -3-[[[4-[ [(4- -1- ) ] ] ] ] ]-2- -， ，(3Z)-， (1:1) ， C31H33N5O4ꞏC2H6O3S， 649.76 g/mol ， 100 150 120.40 180.60 Medi

Indications

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Reacoes adversas

[ Precaucoes(5.2)] [ Precaucoes(5.3)] - [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1 ，

Precautions

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Dosagem (2.3)] 5.2 DILI ， DILI

Interacoes medicamentosas

7.1 P- (P-gp) CYP3A4 P-gp ， CYP3A4 [ (12.3)] P-gp CYP3A4 ， 60% P-gp CYP3A4 [ (12.3)] ，

Clinical Pharmacology

12 12.1 Como funciona ， (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1-3 (VEGFR) 1-3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 ， (ILD) ATP ， ， ILD nRTK Lck Lyn

Pharmacology and Toxicology

13 13.1 10 30 mg/kg/ MRHD AUC 4 ， MRHD AUC， 100 mg/kg/ 3 ，

Clinical Studies

14 14.1 II 1 [NCT00514683] III 2 [NCT01335464] 3 [NCT01335477] 1231 (IPF) ， ， 150 mg 52 2 3 1 3:2 1 1:1 150 mg ， 52

Avaliacoes do produto (14)

Filtro: Todas as avaliacoes
4.8★★★★★
14 avaliacoes de clientes11 compras verificadas
+o***e· ha 3 semanas
★★★★
+t***3· ha 1 meses
Compra verificada
★★★★★

Descricao

Indicacoes

Used to treat idiopathic pulmonary fibrosis (IPF) in adults, chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype in adults, and to slow the decline of lung function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

Mecanismo de acao

， RTK nRTK RTK PDGFR α β FGFR 1 3 VEGFR 1 3 1 CSF1R Fms -3 FLT-3 FLT-3 ， ILD ATP ， ， ILD

Farmacologia

12.1 Como funciona ， (RTK) (nRTK) RTK (PDGFR) α β (FGFR) 1 3 (VEGFR) 1 3 1 (CSF1R) Fms -3 (FLT-3) FLT-3 ， (ILD) (ATP) ，

Precaucoes

5.1 Child-Pugh B Child-Pugh C [ (8.6) (12.3)] Child-Pugh A [ Dosagem (2.3)] 5.2 DILI ， DILI

Interacoes medicamentosas

7.1 P- (P-gp) CYP3A4 P-gp ， CYP3A4 [ (12.3)] P-gp CYP3A4 ， 60% P-gp CYP3A4 [ (12.3)] ，

Reacoes adversas

[ Precaucoes(5.2)] [ Precaucoes(5.3)] - [ Precaucoes(5.4)] [ Precaucoes(5.5)] [ Precaucoes(5.6)] [ Precaucoes(5.7)] [ Precaucoes(5.8)] 6.1 ，

Informacoes adicionais

Especificacao

100mg*60粒, 150mg*60粒